AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1321859
Drug: Oka strain
RxNorm normalized name: Live attenuated Oka strain varicella vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oka strain live attenuated varicella-zoster virus (VZV) vaccine, administered subcutaneously at doses varying from 1100 to 12,000 pfu, with one cohort receiving 3000 pfu and a 3000 pfu booster 3 months later.
Trial: 1321859
Drug: Oka strain
RxNorm normalized name: Live attenuated Oka strain varicella vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oka strain live attenuated varicella-zoster virus (VZV) vaccine
Trial: 24118368
Drug: One-piece titanium
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-piece titanium implants
Trial: 24118368
Drug: One-piece zirconia
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-piece zirconia implants
Trial: 12075219
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) 0.4 mg/mL applied for 4 minutes
Trial: 6389378
Drug: Oral bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral bumetanide
Trial: 6389378
Drug: Intravenous bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous bumetanide
Trial: 31349792
Drug: 14-day ECG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day ECG monitoring patch (Zio® Patch, iRhythm Technologies)
Trial: 28525614
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg lidocaine (group RL40)
Trial: 28525614
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg lidocaine (group LL1.2)
Trial: 27128611
Drug: Ruxolitinib 25
RxNorm normalized name: ruxolitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 25 mg
Trial: 27128611
Drug: Ruxolitinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 200 mg
Trial: 16386524
Drug: Plasmapheresis (PP)
RxNorm normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmapheresis (PP) and intravenous immunoglobulin (IVIG)
Trial: 337982
Drug: Testosterone cypionate,
RxNorm normalized name: testosterone cypionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate, 200 mg, intramuscularly weekly
Trial: 29096835
Drug: Lipoprotein apheresis
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoprotein apheresis (LA) treatment, weekly for 2 years
Trial: 29096835
Drug: Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum tolerated lipid lowering therapy (control group)
Trial: 21498149
Drug: Emtricitabine (FTC)
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Emtricitabine (FTC) dosed once daily
Trial: 21498149
Drug: Lamivudine (3TC)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (3TC) dosed twice daily
Trial: 19249153
Drug: Intermittent hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent hormonal therapy (IHT) with cyproterone acetate (CPA) 200mg for 2 weeks and then monthly depot injections of a luteinising hormone-releasing hormone (LHRH) analogue plus 200mg of CPA daily during induction. Patients randomised to the intermittent arm ceased treatment.
Trial: 19249153
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with 200mg of CPA daily plus an LHRH analogue.
Trial: 19249153
Drug: Intermittent hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent hormonal therapy (IHT)
Trial: 9383182
Drug: Metoprolol (50-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50-250 mg/day)
Trial: 9383182
Drug: Prazosin (3-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (3-20 mg/day)
Trial: 3684175
Drug: aminoglutethimide 1000
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aminoglutethimide 1000 mg/day + hydrocortisone 20 mg/day
Trial: 3684175
Drug: aminoglutethimide 250
RxNorm normalized name: aminoglutethimide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aminoglutethimide 250 mg/day
Trial: 27011002
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) - once-daily (long-acting) for 4 weeks
Trial: 27011002
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) - highest dose
Trial: 23959630
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate (SrRan) 2 g per day
Trial: 23959630
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) 70 mg per week
Trial: 20226890
Drug: Ag85B-ESAT-6 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ag85B-ESAT-6 vaccine with IC31 adjuvant
Trial: 20226890
Drug: Ag85B-ESAT-6 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ag85B-ESAT-6 vaccine without IC31 adjuvant
Trial: 18344850
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy only (control)
Trial: 12584366
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme (ACE) inhibitors (among male subjects)
Trial: 12584366
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme (ACE) inhibitors (among female subjects)
Trial: 10321419
Drug: Nabumetone 2000
RxNorm normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabumetone 2000 mg/d
Trial: 10321419
Drug: Sulindac 400
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac 400 mg/d
Trial: 8723378
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release L-DOPA/carbidopa (100/25 mg)
Trial: 6412390
Drug: Sodium heparin
RxNorm normalized name: Heparin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium heparin 5000 IU subcutaneously every 12 hours for 7 days
Trial: 6412390
Drug: Semi-synthetic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-synthetic heparin analogue (SSHA) 75 mg subcutaneously every 12 hours for 7 days
Trial: 31957555
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplement (2000 IU/day)
Trial: 27910150
Drug: ONO-2952 20
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-2952 20 mg
Trial: 27910150
Drug: ONO-2952 60
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-2952 60 mg
Trial: 19243306
Drug: OXN PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXN PR (60-80 mg/day)
Trial: 19243306
Drug: OXY PR
RxNorm normalized name: Acarboxy prothrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXY PR alone (60-80 mg/day)
Trial: 16331792
Drug: Synovial tissue
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synovial tissue analysis in treatment strategies for rheumatoid arthritis
Trial: 7778636
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol (50 microgram tablets every 3 hours for a maximum of six doses)
Trial: 7778636
Drug: Intracervical dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracervical dinoprostone (0.5 mg every 6 hours for a maximum of three doses)
Trial: 7189333
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (2 mg/kg)
Trial: 7189333
Drug: Lidocaine (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (21 mg/kg)
Trial: 30528459
Drug: Intraneural injection
RxNorm normalized name: bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraneural injection (1ml solution)
Trial: 30528459
Drug: Perineural injection
RxNorm normalized name: ROPIVACAINE HYDROCHLORIDE 2 mg in 1 mL PERINEURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perineural injection (1ml solution)
Trial: 28938956
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg followed by 90 mg twice daily
Trial: 28938956
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg followed by 75 mg daily
Trial: 24117412
Drug: Reduced-fluence photodynamic
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-fluence photodynamic therapy (RDPDT) with Verteporfin (25 J/cm²) followed by intravitreal bevacizumab 1.25 mg
Trial: 24117412
Drug: Reduced-fluence photodynamic
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-fluence photodynamic therapy (RDPDT) with Verteporfin followed by intravitreal bevacizumab
Trial: 21495900
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g E. officinalis powder per day
Trial: 21495900
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g E. officinalis powder per day
Trial: 21495900
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g E. officinalis powder per day
Trial: 19535707
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine administered 30 min before 2-chloroprocaine anesthesia (n = 29)
Trial: 19535707
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine administered after 2-chloroprocaine anesthesia (n = 30)
Trial: 19535707
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine administered after lidocaine anesthesia (n = 28)
Trial: 19535707
Drug: Supplemental morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental morphine equivalents administered in the first 48 h
Trial: 17438515
Drug: Estrogen-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-containing oral contraceptives
Trial: 17438515
Drug: Delayed hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed hormone therapy
Trial: 15110204
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy administered to 134 patients (12%)
Trial: 15110204
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy after propensity score analyses
Trial: 11180010
Drug: Recombinant interleukin-10
RxNorm normalized name: interleukin-10
DrugBank: Interleukin-10 (DB12880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interleukin-10 administered subcutaneously over 6 weeks
Trial: 8092234
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with short protocol using gonadotropin-releasing hormone agonist followed by human menopausal gonadotropin and human chorionic gonadotropin
Trial: 24190112
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m² on days 1, 8, and 15, every 4 weeks)
Trial: 24190112
Drug: Irinotecan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (150 mg/m² on days 1 and 15, every 4 weeks)
Trial: 21944095
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment after initially waiting
Trial: 12707158
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of lactated Ringer's solution 40 mL/kg
Trial: 12707158
Drug: Background infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background infusion of lactated Ringer's solution 5 mL/kg
Trial: 4016830
Drug: Mezlocillin (5-gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mezlocillin (5-gm dose administered intravenously 30 minutes before surgery)
Trial: 4016830
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered intravenously 30 minutes before surgery)
Trial: 24239600
Drug: Hyangsa-Pyeongwi san
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyangsa-Pyeongwi san (HPS) 9.68g at once, three times daily for 4 weeks
Trial: 21869730
Drug: enalapril FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril FA tablet (10 : 0.4 mg, low‐FA group)
Trial: 21869730
Drug: enalapril FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril FA tablet (10 : 0.8 mg, high‐FA group)
Trial: 21869730
Drug: enalapril only
RxNorm normalized name: Enalapril only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril only (10 mg, control group)
Trial: 20569064
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy during tuberculosis therapy
Trial: 20569064
Drug: Tuberculosis therapy
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuberculosis therapy alone
Trial: 18280582
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment for schizophrenia or schizophreniform disorders
Trial: 14653235
Drug: Bougienage and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bougienage and omeprazole (20 mg/day for 12 months)
Trial: 14653235
Drug: Bougienage and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bougienage and ranitidine (300 mg/day for 12 months)
Trial: 1412119
Drug: Budesonide (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (1.6 mg inhaled per day for three weeks)
Trial: 1412119
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg oral per day for eight days)
Trial: 30988711
Drug: BIOF2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BIOF2 treatment (intra-articular BIOF2 application at 0, 1 and 2 months)
Trial: 30988711
Drug: BIOF2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BIOF2 treatment (intra-articular BIOF2 application at 0, 1 and 2 months) excluding patients with class 2 obesity or malalignment
Trial: 30988711
Drug: Usual medical
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medical care (paracetamol/NSAIDs and general care provided by the family physician)
Trial: 20195744
Drug: Ovarian function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian function suppression plus 5 years of tamoxifen with anthracycline-based chemotherapy
Trial: 20195744
Drug: Ovarian function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian function suppression plus 5 years of tamoxifen without chemotherapy (endocrine therapy alone)
Trial: 20195744
Drug: Adjuvant! estimate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant! estimate for endocrine therapy alone
Trial: 20195744
Drug: Adjuvant! estimate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant! estimate for chemoendocrine therapy
Trial: 17919634
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (SMT) with 6 sessions of supportive therapy.
Trial: 11674922
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (sublingual immunotherapy with a biologically standardised extract of three pollens)
Trial: 11674922
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (sublingual immunotherapy) during the second year
Trial: 2882607
Drug: Propoxyphene napsylate
RxNorm normalized name: Propoxyphene Napsylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene napsylate with acetaminophen (PN/A, 100 mg with 650 mg)
Trial: 31679865
Drug: MF59®‐adjuvanted trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59®‐adjuvanted trivalent influenza vaccine (aTIV; Fluad®)
Trial: 31679865
Drug: Highest dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest dosage of antigen in combination with the highest dosage of adjuvant
Trial: 31679865
Drug: Modified aTIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified aTIV formulations
Trial: 26763271
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (1000 impulses and 2.1 bar)
Trial: 24074486
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Clopidogrel dual therapy
Trial: 24074486
Drug: Study group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study group (patients on anti-platelet therapy)
Trial: 20649945
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied pure lavender oil (1 ml of 30% high strength essential lavender oil)
Trial: 18207205
Drug: Astringent solution
RxNorm normalized name: Aluminum Acetate Astringent Solution Packets
DrugBank: Aluminum acetate (DB14518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Astringent solution (5 g L(‐1) tannic acid in distilled water)
Trial: 18207205
Drug: Sweet solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweet solution (40 g L(‐1) sugar in mango tea with no tannins)
Trial: 16415706
Drug: Reduced-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose group
Trial: 16415706
Drug: Fixed-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose group
Trial: 1632166
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.3 mg) + bupivacaine (20 mg)
Trial: 1632166
Drug: Postoperative naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative naloxone infusion (1 microgram/kg/h over 12 h, 0.25 micrograms/kg/h over the next 12 h) + bupivacaine (20 mg) + morphine (0.3 mg)
Trial: 1632166
Drug: Bupivacaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (20 mg)
Trial: 26260354
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii 250 mg
Trial: 26260354
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii 250 mg plus BS 524 mg
Trial: 26260354
Drug: BS 524
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BS 524 mg
Trial: 19362455
Drug: Bitter melon
RxNorm normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter melon (55 ml/24h)
Trial: 19362455
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg/24h)
Trial: 18500525
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml of oral contrast agent
Trial: 18500525
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml of oral contrast agent
Trial: 18500525
Drug: 450 ml
RxNorm normalized name: ALCOHOL 270 mL in 450 mL EXTRACORPOREAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 ml of oral contrast agent